Prognostic value of YKL-40 in solid tumors: a meta-analysis of 41 cohort studies

Abstract Background Serum/plasma YKL-40 can be a useful index that is associated with tumor development. However, the prognostic value of serum/plasma YKL-40 in patients with solid tumors is still unclear. We aimed to utilize the existing literature to investigate the prognostic value of serum/plasma YKL-40 in solid tumors. Methods An extensive literature search for relevant studies was conducted with the Embase, Medline and Web of Science databases. The effect on survival was measured with the hazard ratio (HR). Then, pooled HRs and 95% confidence intervals (CIs) were calculated using the random and fixed-effects models according to the heterogeneity of the included studies. Results This meta-analysis was based on 41 publications and comprised a total of 7762 patients with solid tumors. The pooled HR showed that elevated serum/plasma YKL-40 was significantly associated with poor OS (HR, 1.44; 95% CI 1.33–1.56). We also found that elevated serum/plasma YKL-40 had significant prognostic effects on OS in various cancer subgroups such as gastrointestinal tumors (HR, 1.37; 95% CI 1.18–1.58), ovarian cancer (HR, 2.27; 95% CI 1.69–3.06), melanoma (HR, 1.77; 95% CI 1.18–2.67), lung cancer (HR, 1.73; 95% CI 1.35–2.23), urologic neoplasms (HR, 1.61; 95% CI 1.08–2.40) and glioblastoma (HR, 1.23; 95% CI 1.07–1.42); in contrast, the prognostic effect of serum/plasma YKL-40 was not statistically significant in breast cancer (HR, 1.07; 95% CI 0.98–1.17). Conclusions The available evidence supports the hypothesis that elevated serum/plasma YKL-40 is associated with poor survival in patients with solid tumors and that serum/plasma YKL-40 may serve as a novel prognostic biomarker.

Download Full-text

Prognostic Value of Osteopontin Splice Variant-c Expression in Breast Cancers: A Meta-Analysis

BioMed Research International ◽

10.1155/2016/7310694 ◽

2016 ◽

Vol 2016 ◽

pp. 1-8 ◽

Cited By ~ 5

Author(s):

Chengcheng Hao ◽

Zhiyan Wang ◽

Yanan Gu ◽

Wen G. Jiang ◽

Shan Cheng

Keyword(s):

Breast Cancer ◽

Cancer Patients ◽

Fixed Effects ◽

Prognostic Value ◽

Meta Analysis ◽

Prognostic Significance ◽

Breast Cancers ◽

Breast Cancer Patients ◽

Poor Survival ◽

High Level

Objectives.Osteopontin (OPN) is overexpressed in breast cancers, while its clinical and prognostic significance remained unclear. This study aimed to assess the prognostic value of OPN, especially its splice variants, in breast cancers.Methods.Data were extracted from eligible studies concerning the OPN and OPN-c expression in breast cancer patients and were used to calculate the association between OPN/OPN-c and survival. Two reviewer teams independently screened the literatures according to the inclusion and exclusion criteria based on quality evaluation. Following the processes of data extraction, assessment, and transformation, meta-analysis was carried outviaRevMan 5.3 software.Results. A total of ten studies involving 1,567 patients were included. The results demonstrated that high level OPN indicated a poor outcome in the OS (HR = 2.22, 95% CI: 1.23–4.00, andP=0.008; random-effects model) with heterogeneity (I2=62%) of breast cancer patients. High level OPN-c appeared to be more significantly associated with poor survival (HR = 2.14, 95% CI: 1.51–3.04, andP<0.0001; fixed-effects model) with undetected heterogeneity (I2=0%).Conclusions.Our analyses indicated that both OPN and OPN-c could be considered as prognostic markers for breast cancers. The high level of OPN-c was suggested to be more reliably associated with poor survival in breast cancer patients.

Download Full-text

Can Vaccination Trigger Autoimmune Disorders? A Meta-Analysis

Vaccines ◽

10.3390/vaccines9080821 ◽

2021 ◽

Vol 9 (8) ◽

pp. 821

Author(s):

Marek Petráš ◽

Ivana Králová Lesná ◽

Jana Dáňová ◽

Alexander M. Čelko

Keyword(s):

Meta Analysis ◽

Autoimmune Disorders ◽

Risk Of Bias ◽

Extensive Literature ◽

Primary Analysis ◽

Measures Of Association ◽

Assessment Development ◽

Extensive Literature Search ◽

The Stability

Vaccination as an important tool in the fight against infections has been suggested as a possible trigger of autoimmunity over the last decades. To confirm or refute this assumption, a Meta-analysis of Autoimmune Disorders Association With Immunization (MADAWI) was conducted. Included in the meta-analysis were a total of 144 studies published in 1968–2019 that were available in six databases and identified by an extensive literature search conducted on 30 November 2019. The risk of bias classification of the studies was performed using the Newcastle–Ottawa Quality Assessment Scale. The strength of evidence was assessed using the Grading of Recommendations Assessment, Development, and Evaluation. While our primary analysis was conducted in terms of measures of association employed in studies with a low risk of bias, the robustness of the MADAWI outcome was tested using measures independent of each study risk of bias. Additionally, subgroup analyses were performed to determine the stability of the outcome. The pooled association of 0.99 (95% confidence interval, 0.97–1.02), based on a total of 364 published estimates, confirmed an equivalent occurrence of autoimmune disorders in vaccinated and unvaccinated persons. The same level of association reported by studies independently of the risk of bias was supported by a sufficient number of studies, and no serious limitation, inconsistency, indirectness, imprecision, and publication bias. A sensitivity analysis did not reveal any discrepancy in the primary result. Current common vaccination is not the cause of any of the examined autoimmune disorders in the medium and long terms.

Download Full-text

Impact of Use of Gastric-Acid Suppressants and Oral Anti-Cancer Agents on Survival Outcomes: A Systematic Review and Meta-Analysis

Cancers ◽

10.3390/cancers12040998 ◽

2020 ◽

Vol 12 (4) ◽

pp. 998 ◽

Cited By ~ 1

Author(s):

Alice Indini ◽

Fausto Petrelli ◽

Gianluca Tomasello ◽

Erika Rijavec ◽

Antonio Facciorusso ◽

...

Keyword(s):

Systematic Review ◽

Gastric Acid ◽

Solid Tumors ◽

Fixed Effects ◽

Negative Impact ◽

Meta Analysis ◽

Soft Tissue Sarcomas ◽

Oral Chemotherapy ◽

Survival Outcomes ◽

Anti Cancer

We performed a systematic review and meta-analysis to evaluate the role of gastric acid suppressant use on outcomes of tyrosine kinase inhibitors (TKIs) and oral chemotherapy. We identified all research evaluating the effect of GAS (gastric acid suppressants) use on patients receiving oral chemotherapy or TKIs for solid tumors. The pooled hazard ratios (HRs) and 95% confidence interval (95%CI) for overall survival (OS) and progression-free survival (PFS) were calculated with a fixed-effects or a random effects model. The study population included n = 16 retrospective studies and 372,418 patients. The series concerned gastrointestinal tract tumors (n = 5 studies), renal cell carcinomas (RCC, n = 3 studies), non-small cell lung cancers (NSCLC, n = 5 studies), and soft tissue sarcomas or mixed histologies solid tumors in n = 3 studies. The pooled HRs for OS and PFS were 1.31 (95%CI: 1.20–1.43; p < 0.01) and 1.3 (95%CI 1.07–1.57; p < 0.01) for GAS and no GAS users, respectively. Only studies of EGFR (epidermal growth factor receptor) mutated NSCLC patients receiving TKIs and those with colorectal cancer receiving oral chemotherapy showed a significant correlation between GAS and poor survival. Our study supports the evidence of a possible negative impact of concomitant GAS therapy on survival outcomes of patients receiving oral anti-cancer drugs.

Download Full-text

Prognostic value of Kindlin-2 expression in patients with solid tumors: a meta-analysis

Cancer Cell International ◽

10.1186/s12935-018-0651-7 ◽

2018 ◽

Vol 18 (1) ◽

Cited By ~ 1

Author(s):

Sheng Liu ◽

Sheng Chen ◽

Kaige Ma ◽

Zengwu Shao

Keyword(s):

Solid Tumors ◽

Prognostic Value ◽

Meta Analysis

Download Full-text

Prognostic Value of Nicotinamide N-Methyltransferase Expression in Patients With Solid Tumors: A Systematic Review and Meta-Analysis

Frontiers in Physiology ◽

10.3389/fphys.2018.01407 ◽

2018 ◽

Vol 9 ◽

Cited By ~ 2

Author(s):

Shimeng Li ◽

Lu Qiao ◽

Zhaowei Yang ◽

Chengyan He

Keyword(s):

Systematic Review ◽

Solid Tumors ◽

Prognostic Value ◽

Meta Analysis

Download Full-text

Prognostic value of increased KPNA2 expression in some solid tumors: A systematic review and meta-analysis

Oncotarget ◽

10.18632/oncotarget.13863 ◽

2016 ◽

Vol 8 (1) ◽

pp. 303-314 ◽

Cited By ~ 6

Author(s):

Li-Na Zhou ◽

Yue Tan ◽

Ping Li ◽

Ping Zeng ◽

Min-Bin Chen ◽

...

Keyword(s):

Systematic Review ◽

Solid Tumors ◽

Prognostic Value ◽

Meta Analysis

Download Full-text

Tissue inhibitor of metalloproteinase-1 (TIMP-1) as a prognostic biomarker in gastrointestinal cancer: a meta-analysis

PeerJ ◽

10.7717/peerj.10859 ◽

2021 ◽

Vol 9 ◽

pp. e10859

Author(s):

Lili Qin ◽

Yueqi Wang ◽

Na Yang ◽

Yangyu Zhang ◽

Tianye Zhao ◽

...

Keyword(s):

Systematic Reviews ◽

Gastrointestinal Cancer ◽

Fixed Effects ◽

Prognostic Value ◽

Meta Analysis ◽

Tissue Inhibitor Of Metalloproteinase ◽

Cochrane Library ◽

Fixed Effects Model ◽

Tissue Inhibitor ◽

Pretreatment Serum

Background Tissue inhibitor of metalloproteinase 1 (TIMP-1) has recently been shown to be dependent on or independent of Matrix metalloproteinases (MMPs) in its roles in tumorigenesis and progression. This appreciation has prompted various studies assessing the prognostic value of TIMP-1 in patients with gastrointestinal cancer, however, the conclusions were still inconsistent. The aim of this study was to assess the prognostic value of TIMP-1-immunohistochemistry (IHC) staining and pretreatment serum/plasma TIMP-1 level in gastrointestinal cancer survival as well as the association between TIMP-1 and clinicopathologic features. Methods The meta-analysis was registered in the International Prospective Register of Systematic Reviews (PROSPERO; Registration NO. CRD42020185407) and followed the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) statement. A highly sensitive literature search was performed in electronic databases including PubMed, EMBASE and the Cochrane Library. Heterogeneity analysis was conducted using both chi-square-based Q statistics and the I2 test. The pooled hazard ratios (HRs) with 95% confidence intervals (CIs) were calculated to assess the prognostic value of TIMP-1 using the fixed-effects model. Odds ratios (ORs) with 95% CIs were calculated to evaluate the associations between TIMP-1 and clinicopathological characteristics. The meta-analysis was conducted using STATA 12.0 software. Results A total of 3,958 patients from twenty-two studies were included in the meta-analysis. Elevated TIMP-1 levels were significantly associated with poor survival in gastrointestinal cancer (TIMP-1-IHC staining: HR = 2.04, 95% CI [1.59–2.61], I2 = 35.7%, PQ = 0.156; pretreatment serum/plasma TIMP-1 levels: HR = 2.02, 95% CI [1.80–2.28], I2 = 0%, PQ = 0.630). Moreover, clinicopathological parameter data analysis showed that elevated TIMP-1 levels were significantly associated with lymph node metastasis (N1/N2/N3 vs N0: OR = 2.92, 95% CI [1.95–4.38]) and higher TNM stages (III/IV vs I/II: OR = 2.73, 95% CI [1.23–6.04]). Conclusion Both TIMP-1-positive IHC staining and high serum/plasma TIMP-1 levels are poor prognostic factors for the survival of gastrointestinal cancer. In addition, TIMP-1 overexpression was correlated with more advanced clinicopathological features.

Download Full-text

Platinum-based neoadjuvant chemotherapy for triple-negative breast cancer: a systematic review and meta-analysis

Journal of International Medical Research ◽

10.1177/0300060520964340 ◽

2020 ◽

Vol 48 (10) ◽

pp. 030006052096434

Author(s):

Zhen-Yu Li ◽

Zhen Zhang ◽

Xiao-Zhong Cao ◽

Yun Feng ◽

Sha-Sha Ren

Keyword(s):

Breast Cancer ◽

Neoadjuvant Chemotherapy ◽

Triple Negative Breast Cancer ◽

Triple Negative ◽

Meta Analysis ◽

Complete Response ◽

Extensive Literature ◽

Extensive Literature Search ◽

Positive Breast Cancer

Background Triple-negative breast cancer (TNBC) is associated with higher aggressiveness and mortality than hormone-positive breast cancer because of the lack of approved therapeutic targets. Patients with TNBC who attain a pathological complete response (pCR) after neoadjuvant chemotherapy have improved survival. Platinum-based agents show promising activity in TNBC; however, their use remains controversial. We conducted a meta-analysis to assess the role of platinum-based agents in neoadjuvant chemotherapy in patients with TNBC. Methods We performed an extensive literature search of the Pubmed, Embase, and Cochrane databases. We calculated pooled odds ratios (OR) with 95% confidence intervals (CI) for the identified studies. Results Eight randomized controlled trials with 1345 patients were included in the analysis. The addition of platinum-based agents improved pCR compared with neoadjuvant therapy based on anthracyclines, cyclophosphamide, taxanes, and fluorouracil (49.1% vs. 35.9%; OR: 1.87, 95% CI: 1.23–2.86). Hematological adverse events were similar in both groups, except for more thrombocytopenia in the platinum-based group (OR: 7.96, 95% CI: 3.18–19.93). Conclusion The addition of platinum-based agents to neoadjuvant chemotherapy improved pCR rates in patients with TNBC, with a slight increase in hematological toxicities. Platinum-based agents might thus be an accessible and economically viable option in patients with TNBC.

Download Full-text